(Q37960141)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Specific delivery of kinase inhibitors in nonmalignant and malignant diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Marike Marjolijn van Beuge

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Klaas Poelstra

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

23 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Delivery

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

59-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111941%20AND%20SRC:MED&resulttype=core&format=json

Protein kinase inhibitors: contributions from structure to clinical compounds

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Targeting non-malignant disorders with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Proteus in the world of proteins: conformational changes in protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Selectively nonselective kinase inhibition: striking the right balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Kinase inhibitors: a new approach to rheumatoid arthritis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

"Go upstream, young man": lessons learned from the p38 saga

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Pathogenesis of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Renal tubulointerstitial fibrosis: common but never simple.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Targeted cancer therapies in the twenty-first century: lessons from imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Mechanisms of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Mannose-6-phosphate/insulin-Like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

ROCK inhibitor, Y-27632, inhibits anoxia-reoxygenation-induced contraction of hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Therapeutic significance of Y-27632, a Rho-kinase inhibitor, on the established liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Rho and p38 MAP kinase signaling pathways mediate LPA-stimulated hepatic myofibroblast migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Chronic kidney disease: the global challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Renal fibrosis: novel insights into mechanisms and therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Specific drug delivery to the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Transforming growth factor-beta regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Inflammatory cytokines in vascular dysfunction and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Delivering nanomedicine to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Tumor regression by targeted gene delivery to the neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625

Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2012.638625